At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
The standard approach to controlling pain after mastectomy includes intravenous and oral pain-relieving medications. In this study, researchers are determining if adding a long-acting local anesthetic, bupivacaine, into the wound at the end of the operation is more effective at reducing pain than the standard medications alone for women having a mastectomy on one side with no immediate reconstruction afterward.
-
KIF5B/RET is an abnormal gene that leads to the growth of lung cancer cells. Cabozantinib inhibits the effects of this gene. In addition, this drug interferes with other pathways that also cause cancer cells to grow, form new blood vessels, and spread to other parts of the body.
-
Researchers want to find the best doses of BNT323 and BNT327 to treat breast cancer. The people in this study have breast cancer that has spread and keeps growing after treatment.
-
Researchers are assessing a new combination therapy for neuroblastoma that has a high chance of coming back after treatment. This study is for children with high-risk neuroblastoma who have not gotten more than 1 chemotherapy cycle.
-
Researchers want to see if giving stereotactic radiosurgery (SRS) after osimertinib is better than osimertinib alone for advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that metastasized (spread) to the brain. Their cancers have a mutation (change) in the EGFR gene, and they are taking or planning to take osimertinib.
-
Researchers want to find the best dose of INCB160058 to treat myeloproliferative neoplasms such as myelofibrosis. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change) in the JAK2 gene.
-
Studies have shown that patients with newly diagnosed localized non-germinomatous germ cell tumors (NGGCT) of the brain or spinal cord whose disease responds well to chemotherapy before receiving radiation therapy are more likely to be free of the disease for a longer time than patients in whom chemotherapy is less effective.
- A Phase II Study of Photobiomodulation Therapy in Children and Adults with Oral Graft-versus-Host Disease after Stem Cell Transplantation
Full Title A Multi-center, Phase II, Randomized Double-blind Trial to Evaluate the Efficacy and Safety of PhotobiomoduLatIon for the Treatment of Oral Chronic Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation (The LIGHT Trial)
Purpose
The purpose of this study is to assess the safety and effectiveness of a specialized light treatment for children and adults with chronic graft-versus host disease (GVHD) of the mouth (oral GVHD) that has not improved after standard treatment. GVHD is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient’s body and cause serious health problems. Oral GVHD can cause mouth inflammation, pain, and sores.
The light treatment in this study is called photobiomodulation (PBM) therapy. PBM uses a device with red and near infrared light to help wounds heal, decrease inflammation, and reduce pain on the parts of the body where it is applied.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have chronic GVHD of the mouth that is not getting better despite standard treatment.
- This study is for people age 4 and older.
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Alina Markova at 646-608-2342.
Protocol
22-271Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05675930ClinicalTrials.gov
-
Researchers are assessing a lower dose of standard radiation therapy after chemotherapy in young people with germinomas. The patients in this study have germinomas of the central nervous system (brain or spinal cord).  It is hoped that this new approach can destroy germinomas with fewer long-term side effects.
- A Phase 1/2 Study of CBL0137 to Treat Advanced Solid Tumors in Children and Young Adults
Full Title A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma (PEPN2111) (CIRB)
Purpose
Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.
The best dose was already found in the first part of this study. The people in this study will now be limited to children and young adults with osteosarcoma or certain types of brain or brain stem tumors (gliomas). In addition, their cancers came back or keep growing even with treatment.
CBL0137 blocks signals between molecules inside a cell. Blocking these signals may kill cancer cells. CBL0137 is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You or your child must:
- Have osteosarcoma or a brain or brain stem glioma that keeps growing even with treatment.
- Have recovered from the serious side effects of prior therapies before getting CBL0137.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be between the ages of 1 and 30 years.
Contact
For more information or to see if you or your child can join this study, please call 833-MSK-KIDS.
Protocol
23-215Phase
Phase I/II (phases 1 and 2 combined)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04870944ClinicalTrials.gov